Cytek Biosciences, Inc. (CTKB) Stock

About Cytek Biosciences, Inc.

Cytek Biosciences, Inc. is led by CEO Wenbin Jiang, publicly traded since 2021.

Cytek Biosciences, Inc. (CTKB) stock trades at $5.59 with a market capitalization of $726.60M. The stock is valued at a negative price-to-earnings (P/E) ratio of -9.42, reflecting a net loss over the last twelve months, price-to-book of 2.36, price-to-sales of 3.67. Over the past 52 weeks the stock has ranged between $3.31 and $6.18, and currently trades 9.5% below its 52-week high.

On profitability, Cytek Biosciences, Inc. generates a return on equity (ROE) of -23.53% (negative, reflecting a net loss), return on capital employed of -12.31%, an operating margin of -19.90%, a net profit margin of -38.98%.

Cytek Biosciences, Inc. by the numbers, 2019–2025

Between 2019 and 2025 Cytek Biosciences, Inc. reported revenue of $58.0M rising to $201.0M, a change of +246.6% across 7 years. Compounded, revenue has grown 16.7% a year over five years, 7.0% over three, 0.5% over the last twelve months. Net profit fell to $-67.0M.

Operating margin went from -29.8% in 2019 to -20.0% in 2025, a gain of 9.8 percentage points. The most recent net margin is -38.98%. On a trailing twelve-month basis to Jun '26, revenue is $206.0M and net profit $-80.0M.

Borrowings stand at $24.0M, cash from operations was $-5.0M in the latest year, positive in 4 of the last 7.

Return on equity has averaged -4.5% over five years, and was -19.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Cytek Biosciences, Inc. (CTKB) — frequently asked questions